News & Media Center

 

Press Releases

 
 

Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 26th Annual Piper Jaffray Healthcare Conference

BETHESDA, Md., November 25, 2014 (GLOBE NEWSWIRE) – Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it will webcast its corporate presentation at the 26th Annual Piper Jaffray Healthcare Conference taking place Tuesday, December 2, 2014 at 10:50 A.M. ET.

The presentation will be webcast live and may be accessed from the Event Calendar page of Sucampo’s website at investor.sucampo.com . Presentation slides will be available via the webcast links. A replay of the webcast will also be available on the Company’s website for several days after the live event. To ensure a timely connection, it is recommended that users register at least 15 minutes prior to the scheduled webcast.

 

About Sucampo Pharmaceuticals, Inc.

Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA® and RESCULA® – and a pipeline of drug candidates in clinical development. A global company, Sucampo is headquartered in Bethesda, Maryland, and has operations in Japan, Switzerland and the United Kingdom. For more information, please visit www.sucampo.com.

The Sucampo logo is the registered trademark and the tagline, The Science of Innovation, is a registered/pending trademark of Sucampo AG. AMITIZA is a registered trademark of Sucampo AG. RESCULA is a registered trademark of R-Tech Ueno, Ltd, and has been licensed to Sucampo AG.

 

Follow us on Twitter (@Sucampo_Pharma). Follow us on LinkedIn (Sucampo Pharmaceuticals).

Twitter LinkedIn

 

Sucampo Forward-Looking Statement

 

This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, future financial and operating results, and other statements that are not historical facts. The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the impact of pharmaceutical industry regulation and health care legislation; Sucampo’s ability to accurately predict future market conditions; dependence on the effectiveness of Sucampo’s patents and other protections for innovative products; the risk of new and changing regulation and health policies in the U.S. and internationally and the exposure to litigation and/or regulatory actions. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. satellite pictures Sucampo undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this presentation should be evaluated together with the many uncertainties that affect Sucampo’s business, particularly those mentioned in the risk factors and cautionary statements in Sucampo’s most recent Form 8-K and 10-K, which Sucampo incorporates by reference.

 

Contact:

Silvia Taylor

Senior Vice President, Investor Relations and Corporate Communications

Sucampo Pharmaceuticals, Inc.

1-240-223-3718

staylor@sucampo.com

 
 

For MEDIA inquiries please contact:

Silvia Taylor

Senior Vice President, Investor Relations and Corporate Affairs

Email: media@sucampo.com

Phone: +1-240-223-3718

 
Contact Us
 
Tel: +1-301-961-3400